Press Releases Cardiol Therapeutics Inc.

Equities

CRDL

CA14161Y2006

Market Closed - Toronto S.E. Other stock markets 01:30:00 28/06/2024 am IST			5-day change	1st Jan Change
2.74 ^CAD	-1.79%		+7.03%	+149.09%

26/06	ROTH MKM Initiates Coverage on Cardiol Therapeutics With Buy Rating, $10 Price Target	MT
13/06	Sector Update: Health Care Stocks Ease Late Afternoon	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders	27/06	NE
Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT	25/06	NE
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients	17/06	AQ
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis	13/06	NE
Surging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development (CRDL,JAZZ, NVO, AZN, SNY)	11/06	AQ
Surging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development	11/06	AQ
Sector Spotlight: Orphan Drug Developers With Significant Upside	03/06	AQ
Analysts Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL)	28/05	AQ
Analystsâ€™ Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics	28/05	AQ
CARDIOL THERAPEUTICS : CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS THREE MONTHS ENDED MARCH 31, 2024 (EXPRESSED IN CANADIAN DOLLARS) - Form 6-K	15/05	PU
Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024	14/05	NE
Cardiol Therapeutics : Notice of Meeting and Record Date - Form 6-K	26/04	PU
Cardiol Therapeutics Announces Year-End 2023 Update on Operations	02/04	NE
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis	21/02	NE
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis	15/02	NE
Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market	24/01	NE
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis	09/01	NE
Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot	05/12	NE
Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases	16/11	NE
CARDIOL THERAPEUTICS : CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 - Form 6-K	15/11	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Cardiol Therapeutics Inc.

Equities

CRDL

CA14161Y2006

Press Releases

Filters